Population pharmacokinetic analysis evaluates bepirovirsen exposure in healthy adults and chronic hepatitis B infection, highlighting factors for dosing regimen design.
Bepirovirsen is a novel antisense oligonucleotide in development for chronic hepatitis B virus (HBV) infection therapy. Understanding the impact that clinical characteristics may have on bepirovirsen exposure is important for determining efficacious and well-tolerated dosing regimens. This analysis evaluated demographics and clinical characteristics associated with bepirovirsen exposure using a population pharmacokinetic (PK) analysis.
No takes yet. Share an insight, caveat, or question.
Youssef et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: